Published in Lancet on May 27, 2000
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ (2009) 6.13
Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ (2013) 3.51
In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother (2002) 3.17
Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis (2012) 2.67
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother (2001) 2.21
The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol (2008) 2.19
Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis (2011) 1.95
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol (2008) 1.95
Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A (2004) 1.91
The treatment of influenza with antiviral drugs. CMAJ (2003) 1.89
Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother (2001) 1.89
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res (2008) 1.86
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother (2001) 1.62
Importance of respiratory viruses in acute otitis media. Clin Microbiol Rev (2003) 1.60
Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J (2011) 1.59
Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother (2008) 1.55
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis (2012) 1.49
Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. Ann Emerg Med (2013) 1.47
Randomized controlled trial of the effect of regular paracetamol on influenza infection. Respirology (2015) 1.47
Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis (2003) 1.45
Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011. PLoS One (2012) 1.43
Influenza. Crit Care Med (2008) 1.39
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother (2009) 1.37
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun (2013) 1.37
Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine. PLoS Comput Biol (2011) 1.33
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother (2010) 1.33
How I treat influenza in patients with hematologic malignancies. Blood (2009) 1.32
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med (2010) 1.24
Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis (2011) 1.20
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One (2013) 1.19
The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013. Can J Infect Dis Med Microbiol (2012) 1.19
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother (2013) 1.17
The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed (2007) 1.16
Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother (2010) 1.15
Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect (2008) 1.15
Should lower respiratory tract secretions from intensive care patients be systematically screened for influenza virus during the influenza season? Crit Care (2012) 1.14
Management of influenza symptoms in healthy adults. J Gen Intern Med (2003) 1.13
To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS One (2010) 1.13
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother (2011) 1.12
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res (2013) 1.12
Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore. Emerg Infect Dis (2006) 1.11
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J (2011) 1.10
Effect of rapid influenza testing on the clinical management of paediatric influenza. Influenza Other Respir Viruses (2009) 1.09
Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J Mol Genet Med (2008) 1.07
Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza. Emerg Infect Dis (2007) 1.05
Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother (2011) 1.04
Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother (2008) 0.99
Heat shock protein 70 inhibits the activity of Influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo. PLoS One (2011) 0.98
Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther (2012) 0.98
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother (2013) 0.97
Can antiviral drugs contain pandemic influenza transmission? PLoS One (2011) 0.97
Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Antimicrob Agents Chemother (2013) 0.97
Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One (2012) 0.97
Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol (2014) 0.96
Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness. Front Microbiol (2016) 0.96
Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico. BMC Infect Dis (2012) 0.93
Oseltamivir in human avian influenza infection. J Antimicrob Chemother (2010) 0.93
Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respir Viruses (2007) 0.91
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment. Int J Chron Obstruct Pulmon Dis (2007) 0.90
Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection. J Clin Microbiol (2002) 0.90
Estimating antiviral effectiveness against pandemic influenza using household data. J R Soc Interface (2008) 0.90
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob Agents Chemother (2012) 0.89
The use of antiviral drugs for influenza: recommended guidelines for practitioners. Can J Infect Dis Med Microbiol (2006) 0.89
Community pharmacy rapid influenza A and B screening: A novel approach to expedite patient access to care and improve clinical outcomes. Can Pharm J (Ott) (2016) 0.88
Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning. Influenza Other Respir Viruses (2007) 0.87
Outcome of pandemic H1N1 pneumonia: clinical and radiological findings for severity assessment. Korean J Intern Med (2011) 0.87
Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog (2013) 0.86
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression. Antimicrob Agents Chemother (2015) 0.85
A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis (2014) 0.85
Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. Antimicrob Agents Chemother (2012) 0.84
3,4-Dicaffeoylquinic Acid, a Major Constituent of Brazilian Propolis, Increases TRAIL Expression and Extends the Lifetimes of Mice Infected with the Influenza A Virus. Evid Based Complement Alternat Med (2011) 0.84
Factors influencing the diagnostic accuracy of the rapid influenza antigen detection test (RIADT): a cross-sectional study. BMJ Open (2014) 0.83
Viral-bacterial interactions-therapeutic implications. Influenza Other Respir Viruses (2013) 0.83
Clinical diagnosis of influenza in the ED. Am J Emerg Med (2015) 0.82
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. J Antimicrob Chemother (2013) 0.82
The neuropsychiatric aspects of influenza/swine flu: A selective review. Ind Psychiatry J (2011) 0.82
Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study. Medicine (Baltimore) (2015) 0.81
ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION. Drugs Future (2010) 0.81
Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic. Clin Infect Dis (2015) 0.81
Oseltamivir (tamiflu) induced depressive episode in a female adolescent. Psychiatry Investig (2010) 0.80
An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. Front Microbiol (2015) 0.80
The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med Microbiol Immunol (2007) 0.79
The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology (2008) 0.78
Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015. Can J Infect Dis Med Microbiol (2015) 0.78
Selection of predicted siRNA as potential antiviral therapeutic agent against influenza virus. Bioinformation (2011) 0.78
Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impact. PLoS Curr (2009) 0.78
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. Front Microbiol (2016) 0.78
Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial. Trials (2015) 0.78
Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013. Antivir Ther (2015) 0.77
Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections. PLoS One (2016) 0.77
Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales. PLoS One (2013) 0.77
Performance of rapid influenza testing in hospitalized children. Eur J Clin Microbiol Infect Dis (2010) 0.77
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Patient participation in decision-making. Soc Sci Med (1998) 8.05
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract (1995) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med (1999) 3.98
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet (1999) 3.61
Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother (2003) 3.24
Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med (2005) 3.21
Identification of human mononuclear leucocyte populations by esterase staining. Clin Exp Immunol (1977) 3.12
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc (1988) 2.82
Management of traumatic intracranial haematoma. Br Med J (Clin Res Ed) (1982) 2.79
Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc (2001) 2.67
A case of human endocarditis due to Streptococcus suis in North America. Rev Infect Dis (1992) 2.63
Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet (1975) 2.61
Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci U S A (1986) 2.48
Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (1987) 2.31
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol (1995) 2.23
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1996) 2.12
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Spatial and temporal operation of the Scotia Sea ecosystem: a review of large-scale links in a krill centred food web. Philos Trans R Soc Lond B Biol Sci (2007) 1.95
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs (2001) 1.74
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
In vitro replication of adeno-associated virus DNA. Proc Natl Acad Sci U S A (1992) 1.60
Identification of virus causing recent seal deaths. Nature (1988) 1.58
Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care (2005) 1.57
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Severe lithium intoxication: management without dialysis and report of a possible teratogenic effect of lithium. Can Med Assoc J (1971) 1.54
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
Distribution and removal of human serum albumin-technetium 99m instilled intranasally. Br J Clin Pharmacol (1976) 1.52
Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis (2000) 1.51
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis (1997) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
The use of the laryngeal mask airway in primary anaesthesia. Anaesthesia (1990) 1.48
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol (2000) 1.43
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer (2011) 1.41
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Oral oseltamivir in human experimental influenza B infection. Antivir Ther (2000) 1.39
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Retracted High rate of human papillomavirus type 16 infection in cytologically normal cervices. Lancet (1989) 1.38
Accuracy of a computer-based anaesthetic audit system. Anaesthesia (1993) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol (2000) 1.38
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infect Immun (2001) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34